# Construction and Identification of Inflammation-Related TF–mRNA–miRNA Coexpression Network and Immune Infiltration in Parkinson's Disease

**Authors:** Zhuzhen Shen, Jieli Zhang, Xiuna Jing, Enxiang Tao

PMC · DOI: 10.1155/padi/2323585 · Parkinson's Disease · 2025-05-07

## TL;DR

This study identifies four inflammation-related genes and builds a regulatory network to better understand Parkinson's disease mechanisms.

## Contribution

The paper introduces a novel TF–mRNA–miRNA coexpression network and validates inflammation-related biomarkers in Parkinson's disease.

## Key findings

- Four key inflammation-related differential expression genes (CXCR4, LEP, SLC18A2, TAC1) were identified and validated.
- Key pathways and coexpression networks related to Parkinson's disease were uncovered through biological function analysis.
- Increased CD4 T-cell infiltration was found to be potentially linked to the onset of Parkinson's disease.

## Abstract

Background: Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. Inflammation, marked by the infiltration of inflammatory mediators and the proliferation of inflammatory cells, is closely linked to PD. This study aims to identify and validate inflammation-related biomarkers in PD and construct a TF–mRNA–miRNA coexpression network through bioinformatics analysis.

Methods: The PD-associated dataset GSE7621 and inflammation-related genes were downloaded from the GEO Database and GeneCards platform to obtain inflammation-related differential expression genes (IRDEGs). The key IRDEGs were generated by PPI network analysis. The gene expression levels of the key IRDEGs were validated by blood samples from PD patients using QPCR analysis. We utilized the ENCODE, hTFtarget, CHEA, miRWALK, and miRDB databases to obtain upstream and downstream molecular network models for constructing the TF–mRNA–miRNA interaction network of the key IRDEGs. Finally, based on CIBERSORT algorithm, the associations between IRDEs and immune cell infiltration were investigated.

Results: A total of four key IRDEGs (CXCR4, LEP, SLC18A2, and TAC1) were screened and validated. Through biological function analysis, key-related pathways and coexpression networks of PD were identified. These genes may be closely related to the onset of PD. Additionally, we found that increased CD4 T-cell infiltration might be associated with the occurrence of PD.

Conclusions: We identified four potential inflammation-related treatment target and constructed a TF–mRNA–miRNA regulatory network. This information provides an initial basis for understanding the complex PD regulatory mechanisms.

## Linked entities

- **Genes:** CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852], LEP (leptin) [NCBI Gene 3952], SLC18A2 (solute carrier family 18 member A2) [NCBI Gene 6571], TAC1 (tachykinin precursor 1) [NCBI Gene 6863]
- **Diseases:** Parkinson's disease (MONDO:0005180)

## Full-text entities

- **Genes:** MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, REST (RE1 silencing transcription factor) [NCBI Gene 5978] {aka DFNA27, GINGF5, HGF5, NRSF, WT6, XBR}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, DRD1 (dopamine receptor D1) [NCBI Gene 1812] {aka D1R, DADR, DRD1A}, FOXA2 (forkhead box A2) [NCBI Gene 3170] {aka HNF-3-beta, HNF3B, TCF3B}, IFNA17 (interferon alpha 17) [NCBI Gene 3451] {aka IFN-alphaI, IFNA, INFA, LEIF2C1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, DDC (dopa decarboxylase) [NCBI Gene 1644] {aka AADC}, AGTR1 (angiotensin II receptor type 1) [NCBI Gene 185] {aka AG2S, AGTR1B, AT1, AT1AR, AT1B, AT1BR}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MIR3936 (microRNA 3936) [NCBI Gene 100500865] {aka mir-3936}, IL11 (interleukin 11) [NCBI Gene 3589] {aka AGIF, IL-11}, DRD2 (dopamine receptor D2) [NCBI Gene 1813] {aka D2DR, D2R}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, SUZ12 (SUZ12 polycomb repressive complex 2 subunit) [NCBI Gene 23512] {aka CHET9, IMMAS, JJAZ1}, SLC18A2 (solute carrier family 18 member A2) [NCBI Gene 6571] {aka PKDYS2, SVAT, SVMT, VAT2, VMAT2}, Grb2 (growth factor receptor bound protein 2) [NCBI Gene 81504] {aka Ash-psi}, GATA2 (GATA binding protein 2) [NCBI Gene 2624] {aka DCML, IMD21, MONOMAC, NFE1B}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, GATA1 (GATA binding protein 1) [NCBI Gene 2623] {aka CNSHA9, ERYF1, GATA-1, GF-1, GF1, HAEADA}, MIR4267 (microRNA 4267) [NCBI Gene 100422994], RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, Slc18a2 (solute carrier family 18 (vesicular monoamine), member 2) [NCBI Gene 214084] {aka 1110037L13Rik, 9330105E13, Vmat2}, Lep (leptin) [NCBI Gene 25608] {aka OB, obese}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, TAL1 (TAL bHLH transcription factor 1, erythroid differentiation factor) [NCBI Gene 6886] {aka SCL, TCL5, bHLHa17, tal-1}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, MIR3671 (microRNA 3671) [NCBI Gene 100500854], Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}
- **Diseases:** mitochondrial dysfunction (MESH:D028361), hypoxia (MESH:D000860), motor deficits (MESH:D009461), cerebrovascular diseases (MESH:D002561), bradykinesia (MESH:D018476), rigidity (MESH:D009127), motor (MESH:D000068079), degeneration of dopaminergic (MESH:D009410), loss (MESH:D016388), PD (MESH:D010300), gut dysbiosis (MESH:D064806), limb tremors (MESH:D014202), neuroinflammation (MESH:D000090862), Inflammation (MESH:D007249), immune dysregulation (OMIM:614878), autoimmune diseases (MESH:D001327), HC (MESH:D000067329), malignant tumors (MESH:D009369), dopaminergic (MESH:D009422), neurotoxicity (MESH:D020258), postural instability (MESH:D054972), neurodegeneration (MESH:D019636)
- **Chemicals:** lipopolysaccharide (MESH:D008070), 6-hydroxydopamine (MESH:D016627), calcium (MESH:D002118), AMD3100 (MESH:C088327), dopamine (MESH:D004298), cAMP (-), MPTP (MESH:D015632), TRIzol (MESH:C411644), reactive oxygen species (MESH:D017382)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12077966/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12077966/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12077966/full.md

---
Source: https://tomesphere.com/paper/PMC12077966